Oct 26, 2016 7:35am EDT Matinas BioPharma Presents Preclinical Data of Orally Administered Encochleated Influenza Vaccine in Murine Model at IDWeek 2016
Oct 24, 2016 7:05am EDT Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
Oct 13, 2016 7:05am EDT Matinas BioPharma to Present at the 2nd Annual Dawson James Securities Growth Stock Conference
Sep 28, 2016 7:00am EDT Matinas BioPharma Commences Patient Dosing in NIH-Sponsored Phase 2a Study with Lead Anti-Infective Candidate MAT2203
Sep 07, 2016 7:05am EDT Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Prophylaxis of Invasive Fungal Infections by U.S. FDA
Sep 06, 2016 7:05am EDT Matinas BioPharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on September 13, 2016
Jul 13, 2016 7:00am EDT Matinas BioPharma Announces Presentation of Cryptococcal Meningitis Preclinical Data of MAT2203 at AIDS-Associated Mycosis Meeting 2016
Jun 22, 2016 7:05am EDT Matinas BioPharma Receives Issuance of Key U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
Jun 20, 2016 7:35am EDT Matinas BioPharma Presents Preclinical Data of MAT2501 at ASM Microbe/ICAAC 2016
